Search Site

Zilico Limited

11th Nov '16

UK cervical cancer diagnostic system to be piloted in India as part of TechEmerge’s programme

Zilico Ltd – a developer of a pioneering cervical cancer diagnostic system - has been selected by the IFC, a member of the World Bank Group, to be part of a unique program across India.

TechEmerge is the first programme of its kind that brings together proven technology companies such as Zilico, with leading healthcare providers in emerging markets.

Chosen from 330 innovators across 29 countries, the inaugural program will see the company working with International Oncology Services, with the aim of increasing the early detection of cervical cancer across India and quickly enabling treatment.

ZedScan™ uses the science of Electrical Impedance Spectroscopy (EIS) to detect the development of pre-cancerous abnormalities of the cervix.

The portable, handheld device is already being used in hospitals across the UK and other countries, provides a more accurate diagnosis in real-time, which assists clinicians with better patient management.

In a recent review of over 1500 women referred to an UK colposcopy clinic, the adoption of ZedScan resulted in a significant increase in disease detection and improvements in clinical performance.

The patient case study revealed a 13% increase in detection of high-grade disease (HGCIN) across all patients, with 50% increase reported in women with low-grade cytology. In 92% of these cases, disease was confirmed with a single biopsy.

Cervical cancer, which is caused by Human Papillomavirus infection, is the leading cancer in Indian women. It is the second most common cancer in women worldwide.

It is estimated there are approximately 132,000 new cases diagnosed and 74,000 deaths annually in India, which accounts for nearly a third of the global cervical cancer deaths.

Although colposcopy is an important method in detecting cervical cancer, in practice, the procedure has not drastically changed over the last 90 years, and diagnosis depends on the subjective assessment of visual indicators by the clinician.

Using ZedScan as an adjunct to the existing colposcopy procedure will help clinicians better manage patients and help avoid unnecessary biopsies, treatments and repeat follow-up appointments.

Colposcopy referrals are also expected to increase dramatically following the introduction of HPV screening and ZedScan can provide a cost-effective means to accommodate this growth.

Sameer Kothari, Chief Executive of Zilico Ltd, said: “We are delighted that Zilico has been chosen as one of TechEmerge’s successful matches and look forward to working with International Oncology Services to implement ZedScan and help improve healthcare delivery in India.”

 

ENDS

Editor’s Notes

About IFC

IFC, a member of the World Bank Group, is the largest global development institution focused on the private sector in emerging markets. Working with more than 2,000 businesses worldwide, IFC use their capital, expertise, and network, to create opportunities where they are needed most. In FY15, IFC’s long-term investments in developing countries increased to nearly $18 billion; helping the private sector play an essential role in the global effort to end extreme poverty and boost shared prosperity. IFC has a dedicated venture capital group that invests in sustainable technology-driven ventures that have a positive impact in emerging markets. For more information, visit www.ifc.org

More Information about International Oncology Services

International Oncology is a global cancer care and research  company at the forefront of bringing World class  cancer care to India through expertise, research and collaboration. Promoted by a team of highly passionate health professionals with significant international experience, these centres are a one stop destination for medical oncology, haematology, bone marrow transplant, surgical oncology, radiation oncology and even advanced cancer diagnostics including Gemini GXL Open PET CT System. 

In a strategic collaboration with Fortis Hospital (Noida); Dr. L H Hiranandani Hospital (Mumbai), Fortis Escorts (Delhi), Dr. Sanchetee Hospital and Cancer Institute (Jodhpur), Seth Nandlal Dhoot Hospital ( Aurangabad) &Meditrina (Kollam) ,  International Oncology has established state-of-the-art Cancer Therapy Centres equipped with cutting edge technology and adheres to global benchmarks.

Modeled along the hub and spoke model, to ensure accessibility our organization has several

OUTREACH CENTRES:

Fortis Vivekanand Hospital Kanth Road, Moradabad
Prem Hospital Bishan Sarup Colony, Opp.Bus Stand, Panipat 
Shija Hospitals and Research Institute Langol, Imphal (W)
Godrej Memorial Hospital Pirojshanagar, Vikhroli (E), Mumbai
Guru Nanak Hospital S-341, Gandhi Nagar, Bandra (E), Mumbai     

Additionally, our organization is planning on a large foot print across the country with deep access into multiple geographies. It  also intends to establish its own centers for research and academics with affiliation to well established international centers across the globe.

 

More information about Zilico Ltd

Zilico's product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) technology, applicable to a wide range of neoplastic conditions. The company prides itself on creating innovative technology that removes subjectivity, increases accuracy and delivers results in real-time. Zilico's head office is located in Manchester, UK with a subsidiary office in Sheffield. Manufacturing and R&D functions are also carried out in the UK and Zilico achieved ISO 13485 accreditation in 2013.

For more information about Zilico, please contact:
Zilico Ltd, tel: +44 161 826 7840; email: info@zilico.co.uk or visit www.zilico.co.uk

For press enquiries, please contact:
Julia Price, tel: +44 7737 864 878; e-mail: julia@juliaprice.co.uk

Download the Press Release.